BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 15655719)

  • 1. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
    Nauck MA
    Horm Metab Res; 2004; 36(11-12):852-8. PubMed ID: 15655719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.
    Nauck MA; Meier JJ
    Regul Pept; 2005 Jun; 128(2):135-48. PubMed ID: 15780433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans.
    Dupre J
    Regul Pept; 2005 Jun; 128(2):149-57. PubMed ID: 15780434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential role of glucagon-like peptide 1 in diabetes.
    Meier JJ; Nauck MA
    Curr Opin Investig Drugs; 2004 Apr; 5(4):402-10. PubMed ID: 15134281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes.
    Nauck M
    Diabet Med; 1996 Sep; 13(9 Suppl 5):S39-43. PubMed ID: 8894470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].
    Diamant M; Bunck MC; Heine RJ
    Ned Tijdschr Geneeskd; 2004 Sep; 148(39):1912-7. PubMed ID: 15495988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
    Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
    Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
    Gallwitz B
    Minerva Endocrinol; 2006 Jun; 31(2):133-47. PubMed ID: 16682937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.
    Rachman J; Barrow BA; Levy JC; Turner RC
    Diabetologia; 1997 Feb; 40(2):205-11. PubMed ID: 9049482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1.
    Nauck MA; Walberg J; Vethacke A; El-Ouaghlidi A; Senkal M; Holst JJ; Gallwitz B; Schmidt WE; Schmiegel W
    Regul Pept; 2004 Apr; 118(1-2):89-97. PubMed ID: 14759561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like peptide 1(GLP-1) in biology and pathology.
    Meier JJ; Nauck MA
    Diabetes Metab Res Rev; 2005; 21(2):91-117. PubMed ID: 15759282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes.
    D'Alessio DA; Vahl TP
    Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E882-90. PubMed ID: 15140755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of metabolic state in an animal model of nutrition-dependent type 2 diabetes following treatment with S 23521, a new glucagon-like peptide 1 (GLP-1) analogue.
    Uçkaya G; Delagrange P; Chavanieu A; Grassy G; Berthault MF; Ktorza A; Cerasi E; Leibowitz G; Kaiser N
    J Endocrinol; 2005 Mar; 184(3):505-13. PubMed ID: 15749809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The entero-insular axis in type 2 diabetes--incretins as therapeutic agents.
    Creutzfeldt W
    Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S288-303. PubMed ID: 11460578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incretins and other peptides in the treatment of diabetes.
    Todd JF; Bloom SR
    Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.
    Nauck MA; El-Ouaghlidi A; Gabrys B; Hücking K; Holst JJ; Deacon CF; Gallwitz B; Schmidt WE; Meier JJ
    Regul Pept; 2004 Nov; 122(3):209-17. PubMed ID: 15491793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes.
    Nauck MA; Holst JJ; Willms B; Schmiegel W
    Exp Clin Endocrinol Diabetes; 1997; 105(4):187-95. PubMed ID: 9285204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GLP-1 effect upon the GPI/IPG system in adipocytes and hepatocytes from diabetic rats.
    Márquez L; González N; Puente J; Valverde L; Villanueva-Peñacarrillo ML
    Diabetes Nutr Metab; 2001 Oct; 14(5):239-44. PubMed ID: 11806463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Glucagon-like peptide-1(GLP-1)].
    Wasada T
    Nihon Rinsho; 2004 Jun; 62(6):1175-80. PubMed ID: 15206160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.